ACE1831

DRUG3 trials

Sponsors

Acepodia Biotech, Inc., Tongji Hospital

Conditions

B-cell LymphomaBurkitt LymphomaDLBCLFollicular LymphomaHigh-grade B-cell LymphomaIgG4 Related DiseaseMarginal Zone LymphomaNon Hodgkin Lymphoma

Phase 1

ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

RecruitingNCT05653271

Acepodia Biotech, Inc.B-cell Lymphoma, Burkitt Lymphoma, DLBCL +5

Start: 2023-01-21End: 2027-09-30Target: 42Updated: 2025-08-11

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

RecruitingNCT07061938

Acepodia Biotech, Inc.IgG4 Related Disease

Start: 2026-01-01End: 2027-06-20Target: 30Updated: 2026-02-13

Unknown Phase

ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）

Not yet recruitingNCT07314567

Tongji HospitalSystem Lupus Erythematosus(SLE)

Start: 2026-01-01End: 2027-12-31Target: 22Updated: 2026-01-02

Related Papers

A Phase 1, Open-Label, Multicenter Study of Treatment with ACE1831, Comprised of Allogeneic Gamma Delta T Cells Conjugated to an Anti-CD-20 Antibody, in Patients (Pts) with B-Cell Relapsed/Refractory Non-Hodgkin's Lymphoma (R/R NHL)

Blood2024-11-05